Astrazeneca Ab Drug Patent Portfolio
Astrazeneca Ab owns 13 orange book drugs protected by 101 US patents with Onglyza having the least patent protection, holding only 3 patents. And Bydureon Pen with maximum patent protection, holding 60 patents. Given below is the list of Astrazeneca Ab's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213988 | Methods of treating chronic kidney disease with dapagliflozin | 01 Apr, 2041 | Active |
| US10973836 | Methods of treating heart failure with reduced ejection fraction | 09 Sep, 2040 | Active |
| US11903955 | Methods of treating heart failure with reduced ejection fraction | 09 Sep, 2040 | Active |
| US10973836 | Methods of treating heart failure with reduced ejection fraction | 09 Mar, 2040 | Active |
| US11903955 | Methods of treating heart failure with reduced ejection fraction | 09 Mar, 2040 | Active |
| US11826376 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | 18 Jan, 2040 | Active |
| US11826376 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | 18 Jul, 2039 | Active |
| US11331442 | Drug delivery systems and related methods | 05 Oct, 2038 | Active |
| US11833292 | Drug delivery systems and related methods | 05 Oct, 2038 | Active |
| US10683499 | Compositions and methods for modulating TTR expression | 25 Aug, 2034 | Active |
| US9127276 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US9181549 | Conjugated antisense compounds and their use | 01 May, 2034 | Active |
| US9616028 | Bilayer tablet formulations | 12 May, 2031 | Active |
| US8895033 | Sustained release formulations using non-aqueous carriers | 04 Apr, 2031 | Active |
| US8815258 | Compositions, methods and systems for respiratory delivery of two or more active agents | 17 Mar, 2031 | Active |
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | 26 Nov, 2030 | Active |
| US9616028 | Bilayer tablet formulations | 12 Nov, 2030 | Active |
| US8895033 | Sustained release formulations using non-aqueous carriers | 04 Oct, 2030 | Active |
| US8721615 | Ampoule comprising an ampoule holder | 18 Jul, 2030 | Active |
| US8998876 | Ampoule comprising an ampoule holder | 07 Jul, 2030 | Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | 16 Jun, 2030 | Active |
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems | 28 May, 2030 | Active |
| US8324266 | Compositions, methods and systems for respiratory delivery of two or more active agents | 28 May, 2030 | Active |
| US8703806 | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents | 28 May, 2030 | Active |
| US8808713 | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems | 28 May, 2030 | Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents | 28 May, 2030 | Active |
| US9463161 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems | 28 May, 2030 | Active |
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | 26 May, 2030 | Active |
| US8721615 | Ampoule comprising an ampoule holder | 18 Jan, 2030 | Active |
| US8998876 | Ampoule comprising an ampoule holder | 07 Jan, 2030 | Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | 16 Dec, 2029 | Active |
| US8690837 | Mixing device for a two-chamber ampoule | 19 Nov, 2029 | Active |
| US8827963 | Administering device with holding mechanism | 04 Aug, 2029 | Active |
| US8690837 | Mixing device for a two-chamber ampoule | 19 May, 2029 | Active |
| US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | 19 Feb, 2029 | Active |
| US8827963 | Administering device with holding mechanism | 04 Feb, 2029 | Active |
| US7951400 | Coated tablet formulation and method | 30 Nov, 2028 | Active |
| US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps | 25 Sep, 2028 | Active |
| US9320853 | Method for administering a fluid active substance from a multi-chamber ampoule | 25 Sep, 2028 | Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Sep, 2028 | Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Sep, 2028 | Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Sep, 2028 | Active |
| US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | 19 Aug, 2028 | Active |
| US8216180 | Administering apparatus with functional drive element | 12 Jul, 2028 | Active |
| US8758292 | Administering apparatus with functional drive element | 12 May, 2028 | Active |
| US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps | 25 Mar, 2028 | Active |
| US9320853 | Method for administering a fluid active substance from a multi-chamber ampoule | 25 Mar, 2028 | Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Mar, 2028 | Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Mar, 2028 | Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | 21 Mar, 2028 | Active |
| US8216180 | Administering apparatus with functional drive element | 12 Jan, 2028 | Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | 20 Dec, 2027 | Active |
| US8758292 | Administering apparatus with functional drive element | 12 Nov, 2027 | Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | 20 Jun, 2027 | Active |
| US8329648 | Methods for treating diabetes and reducing body weight | 18 Feb, 2027 | Active |
| US8906851 | Method for treating diabetes | 18 Feb, 2027 | Active |
| US9884092 | Methods for treating diabetes and reducing body weight | 18 Feb, 2027 | Active |
| US8329648 | Methods for treating diabetes and reducing body weight | 18 Aug, 2026 | Active |
| US8906851 | Method for treating diabetes | 18 Aug, 2026 | Active |
| US9884092 | Methods for treating diabetes and reducing body weight | 18 Aug, 2026 | Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method | 04 Apr, 2026 | Active |
| US7456254 | Polymer-based sustained release device | 30 Dec, 2025 | Active |
| US7612176 | Polymer-based sustained release device | 13 Oct, 2025 | Active |
| US8431685 | Polymer-based sustained release device | 13 Oct, 2025 | Active |
| US8461105 | Polymer-based sustained release device | 13 Oct, 2025 | Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method | 04 Oct, 2025 | Active |
| US8628799 | Coated tablet formulation and method | 13 Jul, 2025 | Active |
| US9339472 | Coated tablet formulation and method | 13 Jul, 2025 | Active |
| US7456254 | Polymer-based sustained release device | 30 Jun, 2025 | Active |
| US7612176 | Polymer-based sustained release device | 13 Apr, 2025 | Expired |
| US8431685 | Polymer-based sustained release device | 13 Apr, 2025 | Expired |
| US8461105 | Polymer-based sustained release device | 13 Apr, 2025 | Expired |
| US8101743 | Modulation of transthyretin expression | 01 Apr, 2025 | Expired |
| US7563871 | Polymer-based sustained release device | 15 Oct, 2024 | Expired |
| US9238076 | Polymer-based sustained release device | 15 Oct, 2024 | Expired |
| US7563871 | Polymer-based sustained release device | 15 Apr, 2024 | Expired |
| US9238076 | Polymer-based sustained release device | 15 Apr, 2024 | Expired |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | 31 Jul, 2023 | Expired |
| US6824822 | Residual solvent extraction method and microparticles produced thereby | 09 Apr, 2023 | Expired |
| US6824822 | Residual solvent extraction method and microparticles produced thereby | 09 Oct, 2022 | Expired |
| US7223440 | Residual solvent extraction method and microparticles produced thereby | 03 Mar, 2022 | Expired |
| US7223440 | Residual solvent extraction method and microparticles produced thereby | 31 Aug, 2021 | Expired |
| US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | 16 Feb, 2021 | Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method | 04 Oct, 2020 | Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method | 04 Oct, 2020 | Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor | 04 Oct, 2020 | Expired |
| US6479065 | Process for the preparation of polymer-based sustained release compositions | 10 Aug, 2020 | Expired |
| US6495164 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability | 25 May, 2020 | Expired |
| US6872700 | Methods for glucagon suppression | 14 Jan, 2020 | Expired |
| US6902744 | Exendin agonist formulations and methods of administration thereof | 14 Jan, 2020 | Expired |
| US5686411 | Amylin agonist peptides and uses therefor | 16 Mar, 2019 | Expired |
| US6956026 | Use of exendins for the reduction of food intake | 07 Jan, 2018 | Expired |
| US7741269 | Exendins and exendin agonists for weight reduction and obesity | 07 Jan, 2018 | Expired |
| US7297761 | Pharmaceutical compositions containing exendins | 15 Oct, 2017 | Expired |
| US7521423 | Exendin pharmaceutical compositions | 15 Oct, 2017 | Expired |
| US6114304 | Methods for regulating gastrointestinal motility | 05 Sep, 2017 | Expired |
| US6858576 | Methods for regulating gastrointestinal motility | 06 Jan, 2017 | Expired |
| US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same | 01 Dec, 2016 | Expired |
| US5814600 | Method and composition for treatment of insulin requiring mammals | 29 Sep, 2015 | Expired |
| US6608029 | Methods for regulating gastrointestinal motility | 07 Sep, 2013 | Expired |
Latest Legal Activities on Astrazeneca Ab's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Astrazeneca Ab.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2024 | US8361972 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2024 | US8361972 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2024 | US8361972 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jul, 2024 | US8361972 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329648 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329648 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329648 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329648 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8324266 |
| Recordation of Patent eCertificate of Correction | 09 Apr, 2024 | US11903955 |
| Patent eCofC Notification | 09 Apr, 2024 | US11903955 |
|
Email Notification
Critical
| 09 Apr, 2024 | US11903955 |
| Mail Patent eCofC Notification | 09 Apr, 2024 | US11903955 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Mar, 2024 | US9463161 |
| Mail Certificate of Correction Memo | 13 Mar, 2024 | US11903955 |
Astrazeneca Ab's Drug Patent Litigations
Astrazeneca Ab's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 16, 2015, against patent number US7297761. The petitioner Sanofi-Aventis U.S. LLC, challenged the validity of this patent, with Amylin Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Astrazeneca Ab's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6667061 | May, 2016 |
FWD Entered
(28 Nov, 2017)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
| US6667061 | May, 2016 |
Terminated-Denied
(30 Nov, 2016)
| Alkermes Controlled Therapeutics, Inc. | Luye Pharma Group Ltd. |
| US7297761 | December, 2015 |
Terminated-Denied
(28 Jun, 2016)
| Amylin Pharmaceuticals, LLC | Sanofi-Aventis U.S. LLC |
Astrazeneca Ab Drug Patents' Oppositions Filed in EPO
Astrazeneca Ab drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 30, 2015, by Lek Pharmaceuticals D.D.. This opposition was filed on patent number EP07784499A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP09812292A | Jan, 2021 | Instone, Terry/Read, Howard Graham/Appleyard Lees IP LLP | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Kraus & Weisert Patentanwälte PartGmbB | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Gedeon Richter Plc. | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Galenicum Health S.L.U. | Granted and Under Opposition |
| EP08732695A | Dec, 2020 | Zentiva, k.s. | Granted and Under Opposition |
| EP17203302A | Aug, 2020 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10016112A | Feb, 2020 | Generics (UK) Ltd | Granted and Under Opposition |
| EP10016112A | Jan, 2020 | Instone, Terry/Appleyard Lees IP LLP/Read, Howard | Granted and Under Opposition |
| EP10782113A | Apr, 2019 | Hoefer & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP15181545A | Sep, 2018 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP08716685A | Apr, 2017 | SHL Group AB | Opposition rejected |
| EP10179007A | Mar, 2017 | Galenicum Health S.L. | Patent maintained as amended |
| EP05756474A | Jan, 2017 | Galenicum Health S.L. | Patent maintained as amended |
| EP11180259A | Nov, 2015 | Teva Pharmaceutical Industries Ltd. | Opposition rejected |
| EP11180259A | Nov, 2015 | PHARMATHEN S.A. | Opposition rejected |
| EP06801867A | Sep, 2015 | Generics [UK] Ltd (trading as Mylan) | Revoked |
| EP06801867A | Sep, 2015 | COOLEY LLP | Revoked |
| EP06801867A | Sep, 2015 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP06801867A | Sep, 2015 | PENTAFARMA, Sociedade Técnico-Medicinal, SA | Revoked |
| EP06801867A | Sep, 2015 | Glaxo Group Limited | Revoked |
| EP06801867A | Aug, 2015 | PHARMATHEN S.A. | Revoked |
| EP07784499A | Apr, 2015 | LEK Pharmaceuticals d.d. | Patent maintained as amended |
Astrazeneca Ab's Family Patents
Astrazeneca Ab drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 20.1% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Astrazeneca Ab Drug List
Given below is the complete list of Astrazeneca Ab's drugs and the patents protecting them.
1. Breztri Aerosphere
Breztri Aerosphere is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11331442 | Drug delivery systems and related methods |
05 Oct, 2038
(13 years from now)
| Active |
| US11833292 | Drug delivery systems and related methods |
05 Oct, 2038
(13 years from now)
| Active |
| US8815258 | Compositions, methods and systems for respiratory delivery of two or more active agents |
17 Mar, 2031
(5 years from now)
| Active |
| US10716753 | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
| US8324266 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US8703806 | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US8808713 | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
| US9415009 | Compositions, methods and systems for respiratory delivery of two or more active agents |
28 May, 2030
(5 years from now)
| Active |
| US9463161 | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
28 May, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Breztri Aerosphere's drug page
2. Bydureon
Bydureon is protected by 46 patents, out of which 22 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 May, 2030
(5 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US8361972
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor |
19 Aug, 2028
(3 years from now)
| Active |
| US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps |
25 Mar, 2028
(2 years from now)
| Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8216180 | Administering apparatus with functional drive element |
12 Jan, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US8329648
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8906851
(Pediatric)
| Method for treating diabetes |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US9884092
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8329648 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US8906851 | Method for treating diabetes |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US9884092 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US7456254
(Pediatric)
| Polymer-based sustained release device |
30 Dec, 2025
(7 months from now)
| Active |
| US7612176
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8431685
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8461105
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US7456254 | Polymer-based sustained release device |
30 Jun, 2025
(a month from now)
| Active |
| US7612176 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8431685 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8461105 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US7563871
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US9238076
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US7563871 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US9238076 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US6824822
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
09 Apr, 2023
(2 years ago)
| Expired |
| US6824822 | Residual solvent extraction method and microparticles produced thereby |
09 Oct, 2022
(2 years ago)
| Expired |
| US7223440
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
03 Mar, 2022
(3 years ago)
| Expired |
| US7223440 | Residual solvent extraction method and microparticles produced thereby |
31 Aug, 2021
(3 years ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
| US6479065 | Process for the preparation of polymer-based sustained release compositions |
10 Aug, 2020
(4 years ago)
| Expired |
| US6495164 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(4 years ago)
| Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(4 years ago)
| Expired |
| US6872700 | Methods for glucagon suppression |
14 Jan, 2020
(5 years ago)
| Expired |
| US6956026 | Use of exendins for the reduction of food intake |
07 Jan, 2018
(7 years ago)
| Expired |
| US7741269 | Exendins and exendin agonists for weight reduction and obesity |
07 Jan, 2018
(7 years ago)
| Expired |
| US6858576 | Methods for regulating gastrointestinal motility |
06 Jan, 2017
(8 years ago)
| Expired |
| US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
01 Dec, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon's drug page
3. Bydureon Bcise
Bydureon Bcise is protected by 38 patents, out of which 19 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8895033
(Pediatric)
| Sustained release formulations using non-aqueous carriers |
04 Apr, 2031
(5 years from now)
| Active |
| US8895033 | Sustained release formulations using non-aqueous carriers |
04 Oct, 2030
(5 years from now)
| Active |
| US8361972
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US8329648
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8906851
(Pediatric)
| Method for treating diabetes |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US9884092
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8329648 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US8906851 | Method for treating diabetes |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US9884092 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US7456254
(Pediatric)
| Polymer-based sustained release device |
30 Dec, 2025
(7 months from now)
| Active |
| US7612176
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8431685
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8461105
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US7456254 | Polymer-based sustained release device |
30 Jun, 2025
(a month from now)
| Active |
| US7612176 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8431685 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8461105 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US7563871
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US9238076
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US7563871 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US9238076 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US6824822
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
09 Apr, 2023
(2 years ago)
| Expired |
| US6824822 | Residual solvent extraction method and microparticles produced thereby |
09 Oct, 2022
(2 years ago)
| Expired |
| US7223440
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
03 Mar, 2022
(3 years ago)
| Expired |
| US7223440 | Residual solvent extraction method and microparticles produced thereby |
31 Aug, 2021
(3 years ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
| US6479065 | Process for the preparation of polymer-based sustained release compositions |
10 Aug, 2020
(4 years ago)
| Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(4 years ago)
| Expired |
| US6872700 | Methods for glucagon suppression |
14 Jan, 2020
(5 years ago)
| Expired |
| US6956026 | Use of exendins for the reduction of food intake |
07 Jan, 2018
(7 years ago)
| Expired |
| US7741269 | Exendins and exendin agonists for weight reduction and obesity |
07 Jan, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Bcise's drug page
4. Bydureon Pen
Bydureon Pen is protected by 60 patents, out of which 22 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8721615
(Pediatric)
| Ampoule comprising an ampoule holder |
18 Jul, 2030
(5 years from now)
| Active |
| US8998876
(Pediatric)
| Ampoule comprising an ampoule holder |
07 Jul, 2030
(5 years from now)
| Active |
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 May, 2030
(5 years from now)
| Active |
| US8721615 | Ampoule comprising an ampoule holder |
18 Jan, 2030
(4 years from now)
| Active |
| US8998876 | Ampoule comprising an ampoule holder |
07 Jan, 2030
(4 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US8690837
(Pediatric)
| Mixing device for a two-chamber ampoule |
19 Nov, 2029
(4 years from now)
| Active |
| US8827963
(Pediatric)
| Administering device with holding mechanism |
04 Aug, 2029
(4 years from now)
| Active |
| US8690837 | Mixing device for a two-chamber ampoule |
19 May, 2029
(4 years from now)
| Active |
| US8827963 | Administering device with holding mechanism |
04 Feb, 2029
(3 years from now)
| Active |
| US8439864
(Pediatric)
| Device for administering fluid from a multi-chamber ampoule in incremental steps |
25 Sep, 2028
(3 years from now)
| Active |
| US9320853
(Pediatric)
| Method for administering a fluid active substance from a multi-chamber ampoule |
25 Sep, 2028
(3 years from now)
| Active |
| US8361972
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor |
19 Aug, 2028
(3 years from now)
| Active |
| US8216180
(Pediatric)
| Administering apparatus with functional drive element |
12 Jul, 2028
(3 years from now)
| Active |
| US8758292
(Pediatric)
| Administering apparatus with functional drive element |
12 May, 2028
(3 years from now)
| Active |
| US8439864 | Device for administering fluid from a multi-chamber ampoule in incremental steps |
25 Mar, 2028
(2 years from now)
| Active |
| US9320853 | Method for administering a fluid active substance from a multi-chamber ampoule |
25 Mar, 2028
(2 years from now)
| Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8216180 | Administering apparatus with functional drive element |
12 Jan, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8758292 | Administering apparatus with functional drive element |
12 Nov, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US8329648
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8906851
(Pediatric)
| Method for treating diabetes |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US9884092
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8329648 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US8906851 | Method for treating diabetes |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US9884092 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US7456254
(Pediatric)
| Polymer-based sustained release device |
30 Dec, 2025
(7 months from now)
| Active |
| US7612176
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8431685
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8461105
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US7456254 | Polymer-based sustained release device |
30 Jun, 2025
(a month from now)
| Active |
| US7612176 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8431685 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8461105 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US7563871
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US9238076
(Pediatric)
| Polymer-based sustained release device |
15 Oct, 2024
(6 months ago)
| Expired |
| US7563871 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US9238076 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US6824822
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
09 Apr, 2023
(2 years ago)
| Expired |
| US6824822 | Residual solvent extraction method and microparticles produced thereby |
09 Oct, 2022
(2 years ago)
| Expired |
| US7223440
(Pediatric)
| Residual solvent extraction method and microparticles produced thereby |
03 Mar, 2022
(3 years ago)
| Expired |
| US7223440 | Residual solvent extraction method and microparticles produced thereby |
31 Aug, 2021
(3 years ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
| US6479065 | Process for the preparation of polymer-based sustained release compositions |
10 Aug, 2020
(4 years ago)
| Expired |
| US6495164 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(4 years ago)
| Expired |
| US6667061 | Preparation of injectable suspensions having improved injectability |
25 May, 2020
(4 years ago)
| Expired |
| US6872700 | Methods for glucagon suppression |
14 Jan, 2020
(5 years ago)
| Expired |
| US6956026 | Use of exendins for the reduction of food intake |
07 Jan, 2018
(7 years ago)
| Expired |
| US7741269 | Exendins and exendin agonists for weight reduction and obesity |
07 Jan, 2018
(7 years ago)
| Expired |
| US6858576 | Methods for regulating gastrointestinal motility |
06 Jan, 2017
(8 years ago)
| Expired |
| US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
01 Dec, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bydureon Pen's drug page
5. Byetta
Byetta is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6872700 | Methods for glucagon suppression |
14 Jan, 2020
(5 years ago)
| Expired |
| US6902744 | Exendin agonist formulations and methods of administration thereof |
14 Jan, 2020
(5 years ago)
| Expired |
| US6956026 | Use of exendins for the reduction of food intake |
07 Jan, 2018
(7 years ago)
| Expired |
| US7741269 | Exendins and exendin agonists for weight reduction and obesity |
07 Jan, 2018
(7 years ago)
| Expired |
| US7297761 | Pharmaceutical compositions containing exendins |
15 Oct, 2017
(7 years ago)
| Expired |
| US7521423 | Exendin pharmaceutical compositions |
15 Oct, 2017
(7 years ago)
| Expired |
| US6858576 | Methods for regulating gastrointestinal motility |
06 Jan, 2017
(8 years ago)
| Expired |
| US5424286 | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
01 Dec, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byetta's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Farxiga
Farxiga is protected by 39 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12213988 | Methods of treating chronic kidney disease with dapagliflozin |
01 Apr, 2041
(15 years from now)
| Active |
| US10973836
(Pediatric)
| Methods of treating heart failure with reduced ejection fraction |
09 Sep, 2040
(15 years from now)
| Active |
| US11903955
(Pediatric)
| Methods of treating heart failure with reduced ejection fraction |
09 Sep, 2040
(15 years from now)
| Active |
| US10973836 | Methods of treating heart failure with reduced ejection fraction |
09 Mar, 2040
(14 years from now)
| Active |
| US11903955 | Methods of treating heart failure with reduced ejection fraction |
09 Mar, 2040
(14 years from now)
| Active |
| US11826376
(Pediatric)
| Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
18 Jan, 2040
(14 years from now)
| Active |
| US11826376 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same |
18 Jul, 2039
(14 years from now)
| Active |
| US8685934
(Pediatric)
| Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 Nov, 2030
(5 years from now)
| Active |
| US8721615
(Pediatric)
| Ampoule comprising an ampoule holder |
18 Jul, 2030
(5 years from now)
| Active |
| US7919598
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Jun, 2030
(5 years from now)
| Active |
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 May, 2030
(5 years from now)
| Active |
| US8721615 | Ampoule comprising an ampoule holder |
18 Jan, 2030
(4 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US7851502
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
19 Feb, 2029
(3 years from now)
| Active |
| US8221786
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8361972
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8716251
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor |
19 Aug, 2028
(3 years from now)
| Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US8329648
(Pediatric)
| Methods for treating diabetes and reducing body weight |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8906851
(Pediatric)
| Method for treating diabetes |
18 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8329648 | Methods for treating diabetes and reducing body weight |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US8906851 | Method for treating diabetes |
18 Aug, 2026
(1 year, 3 months from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US7456254
(Pediatric)
| Polymer-based sustained release device |
30 Dec, 2025
(7 months from now)
| Active |
| US8431685
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US8461105
(Pediatric)
| Polymer-based sustained release device |
13 Oct, 2025
(5 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US7456254 | Polymer-based sustained release device |
30 Jun, 2025
(a month from now)
| Active |
| US8431685 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US8461105 | Polymer-based sustained release device |
13 Apr, 2025
(26 days ago)
| Expired |
| US9238076 | Polymer-based sustained release device |
15 Apr, 2024
(1 year, 24 days ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Farxiga's drug page
7. Kombiglyze Xr
Kombiglyze Xr is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8628799 | Coated tablet formulation and method |
13 Jul, 2025
(2 months from now)
| Active |
| US9339472 | Coated tablet formulation and method |
13 Jul, 2025
(2 months from now)
| Active |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
31 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
16 Feb, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kombiglyze Xr's drug page
8. Onglyza
Onglyza is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7951400 | Coated tablet formulation and method |
30 Nov, 2028
(3 years from now)
| Active |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
31 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
16 Feb, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onglyza's drug page
9. Qtern
Qtern is protected by 17 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7919598
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Jun, 2030
(5 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US8221786
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8361972
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8716251
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US8628799 | Coated tablet formulation and method |
13 Jul, 2025
(2 months from now)
| Active |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
31 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qtern's drug page
10. Qternmet Xr
Qternmet Xr is protected by 15 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9616028
(Pediatric)
| Bilayer tablet formulations |
12 May, 2031
(6 years from now)
| Active |
| US9616028 | Bilayer tablet formulations |
12 Nov, 2030
(5 years from now)
| Active |
| US7919598
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Jun, 2030
(5 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US8716251
(Pediatric)
| Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Sep, 2028
(3 years from now)
| Active |
| US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor |
21 Mar, 2028
(2 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US8628799 | Coated tablet formulation and method |
13 Jul, 2025
(2 months from now)
| Active |
| USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
31 Jul, 2023
(1 year, 9 months ago)
| Expired |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qternmet Xr's drug page
11. Symlin
Symlin is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5686411 | Amylin agonist peptides and uses therefor |
16 Mar, 2019
(6 years ago)
| Expired |
| US6114304 | Methods for regulating gastrointestinal motility |
05 Sep, 2017
(7 years ago)
| Expired |
| US5814600 | Method and composition for treatment of insulin requiring mammals |
29 Sep, 2015
(9 years ago)
| Expired |
| US6608029 | Methods for regulating gastrointestinal motility |
07 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symlin's drug page
12. Wainua (autoinjector)
Wainua (autoinjector) is protected by 4 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10683499 | Compositions and methods for modulating TTR expression |
25 Aug, 2034
(9 years from now)
| Active |
| US9127276 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US9181549 | Conjugated antisense compounds and their use |
01 May, 2034
(8 years from now)
| Active |
| US8101743 | Modulation of transthyretin expression |
01 Apr, 2025
(a month ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wainua (autoinjector)'s drug page
13. Xigduo Xr
Xigduo Xr is protected by 13 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9616028
(Pediatric)
| Bilayer tablet formulations |
12 May, 2031
(6 years from now)
| Active |
| US8685934
(Pediatric)
| Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 Nov, 2030
(5 years from now)
| Active |
| US9616028 | Bilayer tablet formulations |
12 Nov, 2030
(5 years from now)
| Active |
| US7919598
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Jun, 2030
(5 years from now)
| Active |
| US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
26 May, 2030
(5 years from now)
| Active |
| US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
16 Dec, 2029
(4 years from now)
| Active |
| US8501698
(Pediatric)
| Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Dec, 2027
(2 years from now)
| Active |
| US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same |
20 Jun, 2027
(2 years from now)
| Active |
| US6515117
(Pediatric)
| C-aryl glucoside SGLT2 inhibitors and method |
04 Apr, 2026
(10 months from now)
| Active |
| US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2025
(4 months from now)
| Active |
| US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
04 Oct, 2020
(4 years ago)
| Expired |
| US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
04 Oct, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xigduo Xr's drug page